anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a traditional Chinese medicine for treating AIDS and a preparation method thereof. The traditional Chinese medicine for treating AIDS is prepared from euphoribia helioscopia, spica prunellae, radix euphorbiae ebracteolatae, cornu cervi pantotrichum, cordyceps, herba chelidonii, Chinese angelica root, ginseng, etc. as raw materials. During the process of preparation, the euphoribia helioscopia is processed by the modern biological technique. The traditional Chinese medicine for treating AIDS not only can control and clear away cancer cells, but also can inhibit and eliminate the disease sources of AIDS so as to prevent the generation of the cells of AIDS. The traditional Chinese medicine for treating AIDS has conspicuous curative effect and does not have large side effect on normal cells. The present invention has the advantages of wide raw material sources and low cost. The present invention is a product which integrates the traditional Chinese medicine theory and the modern biological technique into one body. The present invention can be widely used for treating AIDS and can also be used for preventing and enhancing physical immunity, etc.
The primary objective of this study is to determine if using Total Intravenous Anesthesia with Propofol (TIVA-P sedation) with a regional nerve block will decrease the time to meet discharge criteria. This will be done with patients undergoing shoulder arthroscopic procedures at the Roanoke Ambulatory Surgical Center. Currently, inhaled general anesthesia (GA) with a regional nerve block is utilized for these outpatient arthroscopic procedures. This involves the patient receiving Propofol through an IV to put a patient to sleep, followed by intubation (breathing tube in throat) and the administration of inhaled anesthesia for the duration of the procedure. Another approach for anesthesia in these procedures is TIVA-P sedation. In this protocol the patient receives the same initial amount of Propofol through the IV as they would if they were getting general anesthesia. Once they are asleep, it is maintained with a continuous intravenous administration of Propofol. With this approach, the patient is not intubated and exposed to the same anesthetic agents as general anesthesia. As a result, the patient may not experience the potential side effects associated with general anesthesia. We believe that this will lead to a faster time to meet discharge criteria and also fewer of anesthetic side effects.
Early-life seizures (ELSs) can cause permanent cognitive deficits and network hyperexcitability, but it is unclear whether ELSs induce persistent changes in specific neuronal populations and whether these changes can be targeted to mitigate network dysfunction. We used the targeted recombination of activated populations (TRAP) approach to genetically label neurons activated by kainate-induced ELSs in immature mice. The ELS-TRAPed neurons were mainly found in hippocampal CA1, remained uniquely susceptible to reactivation by later-life seizures, and displayed sustained enhancement in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated (AMPAR-mediated) excitatory synaptic transmission and inward rectification. ELS-TRAPed neurons, but not non-TRAPed surrounding neurons, exhibited enduring decreases in Gria2 mRNA, responsible for encoding the GluA2 subunit of the AMPARs. This was paralleled by decreased synaptic GluA2 protein expression and heightened phosphorylated GluA2 at Ser880 in dendrites, indicative of GluA2 internalization. Consistent with increased GluA2-lacking AMPARs, ELS-TRAPed neurons showed premature silent synapse depletion, impaired long-term potentiation, and impaired long-term depression. In vivo postseizure treatment with IEM-1460, an inhibitor of GluA2-lacking AMPARs, markedly mitigated ELS-induced changes in TRAPed neurons. These findings show that enduring modifications of AMPARs occur in a subpopulation of ELS-activated neurons, contributing to synaptic dysplasticity and network hyperexcitability, but are reversible with early IEM-1460 intervention.
1374199 Polysaccharide films HAYASHIBARA BIOCHEMICAL LABORATORIES Inc 14 July 1972 [23 July 1971 30 Oct 1971] 33204/72 Heading B5B [Also in Divisions C3 B8 and A2] Artificial films, fibres, plates, tubes or capsules having water solubility and utility as coating or wrapping materials, e.g. for foods, comprise pullulan or pullulan and another watersoluble film forming polymer, e.g. amylose, polyvinylalcohol or gelatine and are produced by dissolving the pullulan or pullulan/polymer mixture in water, imparting a shape to the aqueous solution, e.g. by casting or spraying, and then substantially completely removing the water from the solution. Preferably a plasticizing agent, e.g. a polyhydric alcohol such as maltitol, sorbitol or glycerol is also incorporated.
The present invention relates to antigenic peptides of the formula H-Val-X-Y FORMULA I wherein X is a polypeptide residue selected from the group consisting of: Val-Pro-Arg-Arg-Lys-Ala-Lys-Ile; Ser-Gly-Lys-Ala-Arg-Gly-Trp-Phe; Tyr-Tyr-Arg-Asp-Ser-Arg-Ash-Pro-Leu; Phe-Ile-His-Asn-Phe-Lys-Arg-Lys-Gly; Ser-Ile-Glu-Trp-Arg-Lys-Lys-Arg-Tyr-Ser; and Leu-His-Thr-Gly-Glu-Arg-Asp-Trp-His-Leu-Gly, and Y is a hydroxyl group or an amino group. The invention also relates to a method of preparing these peptides. These novel peptides exhibit useful antigenic properties, with respect to Human Immunodeficiency Virus (HIV), formerly known as Human T-cell Lymphotropic Type-III Virus (HTLV-III). Human Immunodeficiency Virus is associated with the diseases known as Acquired Immune Deficiency Syndrome (AIDS) and Aids Related Complex (ARC). The present antigenic peptides are useful for the detection of antibodies active against HIV and are suitable for use as diagnostic agents. The antigenic peptides of the invention have been shown to induce an in vivo immune response in animals, and the in vitro production of monoclonal antibodies.
BACKGROUND: During the summer of 2021, a deadly, unprecedented multiday Heat Dome engulfed western Canada. As a result of this extreme heat event (EHE), emergency dispatchers received an unparalleled increase in incoming 911 calls for ambulance, police, and fire (as first responders) services to attend to hundreds of heat-vulnerable community members succumbing to the heat. With 103 all-time heat records broken during this EHE and indoor temperatures of nearly 40°C, the first responders attending these calls faced extensive job demands and highly challenging operating conditions. Initial investigations have explored the health system-level impacts; however, little has been done to explore the impact on the first responders themselves. Therefore, this study aimed to improve our understanding of EHEs' impacts on the operational capabilities and health of first responders, specifically police, fire, ambulance, and dispatch services.
METHODS: A systematized review and content analysis of media articles published on the 2021 Heat Dome in Canada was conducted (n = 2909), and four media-based composite narratives were developed highlighting police, fire, ambulance, and dispatch services. The Job Demands-Resources (JD-R) model was applied as a theoretical framework for occupational burnout.
RESULTS: The media-based composite narratives highlighted that first responders faced record-breaking call volumes, increased mental-health-related claims, and exhaustive heat-related physiological stress. Using the JD-R model as a theoretical framework for occupational burnout, we identified three measures of stressful job demand: work overload (e.g., the surge in call volume, firefighters responding to medical emergencies), emotional demands (e.g., severe medical emergencies, sudden deaths, unresponsive patients, distraught family members), and physical demands (e.g., resuscitation in personal protective equipment, heat-related illness).
CONCLUSION: The experiences described underscore the importance of supporting first responders during work in extreme heat conditions. These findings have important implications for addressing rising rates of burnout during and following public health crises, such as EHEs, a problem that is increasingly being recognized as a threat to the Canadian public healthcare system.
BACKGROUND: Percutaneous Hepatic Perfusion (PHP) is a liver directed regional therapy recently FDA approved for metastatic uveal melanoma to the liver involving percutaneous isolation of liver, saturation of the entire liver with high-dose chemotherapy and filtration extracorporeally though in line filters and veno-venous bypass. The procedure is associated with hemodynamic shifts requiring hemodynamic support and blood product resuscitation due to coagulopathy.
OBJECTIVE: To assess the cardiac safety and subsequent clinically significant sequalae of this therapy.
METHODS: Consecutive PHP procedures done at our center between 2010-2022 were assessed retrospectively. Cardiac risk factors, post procedural cardiac enzymes, electrocardiograms, and transthoracic echocardiograms along with 90-day cardiac outcomes were reviewed. All data were reviewed by cardio-oncologists at our institution.
RESULTS: Of 37 patients reviewed, mean age was 63 years and 57% were women. 132 procedures were performed with an average of 3.57 procedures per patient. 68.6% of patients had elevated troponin during at least 1 procedure. No patients were found to have acute coronary syndrome, heart failure, unstable arrhythmias, or cardiac death. No patients had notable echocardiographic changes. 10.8% of patients with positive troponin had asymptomatic transient electrocardiographic changes not meeting criteria for myocardial infarction. One patient had non-sustained ventricular tachycardiac intra-operatively which did not recur subsequently. Three patients died from non-cardiac causes within 90-days. There was no oncology treatment interruption, even in those with troponin elevation. In multivariable analysis, a history of hyperlipidemia was a predictor of postoperative troponin elevation. (P = .042).
CONCLUSION: Percutaneous Hepatic Perfusion is safe and associated with a transient, asymptomatic troponin elevation peri-operatively without major adverse cardiac events at 90 days. The observed troponin elevation is likely secondary to coronary demand-supply mismatch related to procedural hemodynamic shifts, hypotension, and anemia.
This program evaluation examines the effectiveness, barriers and facilitators of implementing a geographically targeted program led by salaried CHWs from three Medicaid health plans in collaboration with the Detroit Health Department and Joy Southfield Community Development Corporation. Beneficiaries who reside in the Cody Rouge neighborhood and had more than 3 Emergency Department (ED) visits or at least 1 ambulatory care-sensitive hospitalization in the prior 12 months are randomized to the CHW program or to usual outreach from the health plans. CHWs reach out to eligible beneficiaries to provide a comprehensive assessment of health, behavioral, and social needs; link them to needed resources; and provide necessary follow-up. At 12- month follow up, health plan claims data on ED visits, ambulatory care-sensitive hospitalizations, primary care visits and all related costs will be compared between participants who participated in this program compared with other participants who would have been eligible but were not offered the program (with no effort to contact them).

The investigators hypothesize that patients enrolled in the CHW intervention will experience a reduction in acute care usage resulting in cost savings compared to those receiving usual health plan CHW outreach. This study is among the first to evaluate the impact on health care utilization of augmented services delivered by health plan CHWs for high-utilizing health plan members. This study will provide important information on the sustainability of future health plan CHW programs and provide insights into effective implementation of such programs.
The study consists of a main study and a voluntary, open-label (participants and researchers are aware about the treatment participants are receiving), 24-week study extension. The main study includes a Screening Run-in Period (Week -6 to Week 0), an Open-label Treatment Period (Week 0 to Week 16), an Open-label or Double-blind Treatment Period (Week 16 to Week 52). The main study also includes a Follow-up Period from Week 52 through Week 64 for those participants who will not participate in the 24-week study extension. Participants, participating in 24-week extension (at Week 52), will receive open-label golimumab SC injections every 4 weeks from Week 52 up to Week 72 and will be followed-up up to Week 88. All eligible participants will initiate the treatment with open-label golimumab SC injection every 4 weeks up to Week 12. At Week 16, depending upon the treatment response either participants will continue to receive open-label golimumab SC injection every 4 weeks up to Week 48 or participants will be randomly assigned to receive following 2 treatments: 1- golimumab 50mg SC injection every 4 weeks along with placebo intravenous infusion every 8 weeks through Week 48; 2- Placebo SC injection every 4 weeks along with golimumab 2mg/kg intravenous infusion every 8 weeks through Week 48. At Week 52, participants who choose to participate in the 24-week study extension will receive open-label golimumab 50 mg SC injections every 4 weeks through Week 72. Participants' safety will be monitored throughout the study.
An adrenocorticotropic hormone preparation having a protracted effect contains the reaction product of the hormone and a water-soluble ether of cellulose, suitably one containing a free carboxylic group, e.g. methyl cellulose, sodium carboxymethyl cellulose, hydroxy ethyl cellulose.  Ethers of alcohols having in addition to the alcohol group involved in the ether formation an acid group such as glycollic acid, are preferred.  The preparation is suitably in the form of an aqueous solution containing 0.5 to 5 per cent of the cellulose ether, suitably in the form of a salt, e.g. the sodium salt, and for instance 20 i.u. of the hormone per mol.
An aerosol composition comprises a liquefied propellent, nitroglycerin, a non-volatile liquid desensitizing agent for the nitroglycerin, and an agent solubilizing the nitroglycerin in the propellent. The composition produces a spray suitable for the relief of anginal pain by inhalation. Suitable desensitizing agents include ethers, alcohols and ether-alcohols of the general formula XO(Ro)nY, where X and Y may be hydrogen, alkyl or acyl (substituted or unsubstituted) and R is alkylene or substituted alkylene; the preferred example is propanediol-1,2. The preferred solubilizing agent is ethanol.  The propellent may be a chlorofluoroalkane, ethyl chloride, 1,1,1-trichloroethane, butane, isobutane, propane, or mixtures thereof preferably having a vapour pressure of 15 to 60 lb/in.2 at room temperature.ALSO:An aerosol composition for producing a spray for the relief of anginal pain by inhalation comprises a propellant, nitroglycerine, a desensitizing agent for the nitroglycerine and a solubilizing agent for the nitroglycerine.  The desensitizing agent may be an ether, alcohol or ether-alcohol of the formula XO(RO)nY, where X and Y may be hydrogen, alkyl or acyl (substituted or unsubstituted) and R is alkylene or substituted alkylene; the preferred example is propanediol - 1,2.  The preferred solubilizing agent is ethanol.
This group will continue on their standard diabetes care. They will be required to undergo three periods of blinded continuous glucose monitoring each lasting 20-days at: baseline, 4 months and 8 months. Participants in this group will undergo a hyperinsulinaemic hypoglycaemic clamp study at baseline and 8 months. They will also complete quality of life and diabetes treatment questionnaires at baseline and 8 months.
Additionally to standard of care, measurements for donor-derived cell-free DNA (dd-cfDNA) are performed at months 0, 1, 3, 6, 9, and 12. If absolute levels of dd-cfDNA are \> 50 copies/ml, the patients receive a kidney allograft biopsy. Additionally, kidney allograft biopsies are performed according to standard of care as determined by the treating physicians.
The present invention relates to oral liquid for strengthening bones, which is prepared from ox bone glue, astragalus roots, pilose asiabell roots, honey, etc., particularly traditional Chinese medicine using ox bones as main raw material and pilose asiabell roots, astragalus roots, etc. as auxiliary raw material for nourishing qi and strengthening spleens. The present invention is proposed according to pharmacological medicated experimental results and is prepared by means of extraction and refinement with a scientific method. The present invention contains natural biological calcium, a large amount of bone collagen, amino acid and trace elements needed by human bodies, and chemical components of the present invention are very similar to those of human bones, so the present invention is easy to absorb by human bodies. The present invention is capable of effectively replenishing calcium and phosphorus and promoting bone formation and the union of factured bones. The present invention is also capable of replenishing qi, invigorating spleens, reinforcing kidneys, strengthening bones, preventing and curing rickets and osteoporosis caused by the deficiency of both spleens and kidneys and other diseases caused by the deficiency of calcium and phosphorus and has the special functions of the prevention and treatment of osteoporosis for children, pregnant women, middle-aged people and old people.
BACKGROUND: Brain microglia and infiltrating monocyte-derived macrophages are vital in preserving blood vessel integrity after stroke. Understanding mechanisms that induce immune cells to adopt vascular-protective phenotypes may hasten the development of stroke treatments. IL-33 is a potent chemokine released from damaged cells, such as CNS glia after stroke. The activation of IL-33/ST2 signaling has been shown to promote neuronal viability and white matter integrity after ischemic stroke. The impact of IL-33/ST2 on blood-brain barrier (BBB) integrity, however, remains unknown. The current study fills this gap and reveals a critical role of IL-33/ST2 signaling in macrophage-mediated BBB protection after stroke.
METHODS: Transient middle cerebral artery occlusion (tMCAO) was performed to induce ischemic stroke in wildtype (WT) versus ST2 knockout (KO) male mice. IL-33 was applied intranasally to tMCAO mice with or without dietary PLX5622 to deplete microglia/macrophages. ST2 KO versus WT bone marrow or macrophage cell transplantations were used to test the involvement of ST2+ macrophages in BBB integrity. Macrophages were cocultured in transwells with brain endothelial cells (ECs) after oxygen-glucose deprivation (OGD) to test potential direct effects of IL33-treated macrophages on the BBB in vitro.
RESULTS: The ST2 receptor was expressed in brain ECs, microglia, and infiltrating macrophages. Global KO of ST2 led to more IgG extravasation and loss of ZO-1 in cerebral microvessels 3 days post-tMCAO. Intranasal IL-33 administration reduced BBB leakage and infarct severity in microglia/macrophage competent mice, but not in microglia/macrophage depleted mice. Worse BBB injury was observed after tMCAO in chimeric WT mice reconstituted with ST2 KO bone marrow, and in WT mice whose monocytes were replaced by ST2 KO monocytes. Macrophages treated with IL-33 reduced in vitro barrier leakage and maintained tight junction integrity after OGD. In contrast, IL-33 exerted minimal direct effects on the endothelial barrier in the absence of macrophages. IL-33-treated macrophages demonstrated transcriptional upregulation of an array of protective factors, suggesting a shift towards favorable phenotypes.
CONCLUSION: Our results demonstrate that early-stage IL-33/ST2 signaling in infiltrating macrophages reduces the extent of acute BBB disruption after stroke. Intranasal IL-33 administration may represent a new strategy to reduce BBB leakage and infarct severity.
The invention relates to a traditional Chinese medicine noninvasive-drug for anal fistula and a preparation method and a use method thereof. The drug comprises the following raw materials by weight: 25-35g of haemorrhoids eliminating grass, 3-7g of frankincense and 3-7g of myrrh. The preparation method comprises the following steps: A, weighing the raw materials; B, immersing the raw materials; C, utilizing a cauldron to stew the immersed raw materials to obtain liquid medicine; and D, filtering and concentrating the liquid medicine to obtain the product. When the drug is in a liquid state, the use method of the drug is that the drug is externally applied or jetted to haemorrhoids or a perfusion fistula. When the drug is in a solid state, the use method of the drug is that the drug is externally applied to the haemorrhoids or the perfusion fistula. The traditional Chinese medicine noninvasive-drug can effectively cure anal fistula diseases.
The accuracy of Lifelight's blood pressure measurements was assessed by comparing Lifelight's measurements with measurements made by dual-observer manual auscultation using the same-arm sequential method specified in ISO 81060-2:2018/AMD 1:2020. The accuracy of Lifelight's pulse rate measurements was assessed by comparing Lifelight's measurements with concurrent ECG-derived heart rate values. The participants were resting before their measurements were taken to ensure stable blood pressure. For each Lifelight measurement, two sets of blood pressure measurements were taken using dual-observer manual auscultation. The first measurement was taken before the Lifelight measurement and the second just after. If there was too much variation between the before and after measurement, or between the 2 independent observers, the measurement was discarded and repeated. For this validation procedure, the measurements taken during the original study were re-processed in the new updated algorithm.